TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06233513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exp 3 Speaking Task
Description: Participant will sit in front of a computer screen in a quiet room and to produce speech based on what is on the screen. Participant may see real words or nonsense words to read. Investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. This task takes about one hour to complete.
Study: NCT04653597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Close monitoring
Description: surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS\>8 or responds adequately to a simple order

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal intubation
Description: invasive airway management in order to avoid risk of pulmonary aspiration
Study: NCT05044676

Intervention type: OTHER
Intervention: patients with hepatocellular carcinoma
Description: The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
Study: NCT06208475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
Study: NCT04873752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UDI-001
Description: 2.5 x 10\^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
Study: NCT04990466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IIBR-100
Description: Administration of IIBR-100 vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Administration of a currently-approved vaccine for COVID-19
Study: NCT04599556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD7 CAR-T
Description: Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD7 CAR-T
Description: Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD7 CAR-T
Description: Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
Study: NCT05865236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra-red lamp therapy + Kegal Exercises
Description: The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry air heat group + Kegal Exercises
Description: Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
Study: NCT06244758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone 20 MG Oral Tablet
Description: The intervention is administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention is administered orally.
Study: NCT05156021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-VEGF
Description: To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-VEGF
Description: To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
Study: NCT05688124

Intervention type: DRUG
Group type: OTHER
Intervention: IBI351
Description: IBI351 is administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: IBI351
Description: IBI351 is administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole
Description: Esomeprazole is administered orally
Study: NCT05167643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enituzumab injection+Abesili tablets+Anastrozole tablets
Description: According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
Study: NCT06494046

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT05069857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (anti-PD-1 inhibitor)
Description: The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (anti-VEGFR inhibitor)
Description: The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
Study: NCT05022329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine
Description: This arm receives Pfizer-BioNTech COVID-19 Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine
Description: This arm receives Pfizer-BioNTech COVID-19 Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MODERNA SARS-CoV-2 Vaccine
Description: This arm receives MODERNA SARS-CoV-2 Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MODERNA SARS-CoV-2 Vaccine
Description: This arm receives MODERNA SARS-CoV-2 Vaccine
Study: NCT05598918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early active mobilization
Description: In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early passive mobilization
Description: In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
Study: NCT06771388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal collagen drink
Description: consume 50 g liquid drink daily for 8 consecutive weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-liposomal collagen drink
Description: consume 50 g liquid drink daily for 8 consecutive weeks
Study: NCT05933369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clincal pharmacist intervention
Description: Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes. The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications. In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
Study: NCT03838302

Intervention type: PROCEDURE
Intervention: Transvaginal tissue retrieval via a posterior colpotomy
Description: Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation

Intervention type: PROCEDURE
Intervention: Transabdominal retrieval via trocar
Description: Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
Study: NCT04684446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29
Study: NCT05743907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: DA-2811 Group: DA-2811 + Forxiga placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forxiga
Description: Forxiga Group: Forxiga + DA-2811 placebo
Study: NCT05211583

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum progesterone levels
Description: In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
Study: NCT04826562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine
Description: single tablet antiretroviral
Study: NCT04875000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remineralizing agent I application
Description: Application of UltraEZ remineralizing agent to the bleached teeth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remineralizing agent II application
Description: Application of 2.5% arginine solution to the bleached teeth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remineralizing agent III application
Description: Application of 2.5% nano-hydroxyapatite solution to the bleached teeth
Study: NCT04726969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 mg Oral Tablet
Description: Tablets of 2 mg moxidectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3 mg Oral Tablet
Description: Tablets of 3 mg ivermectin
Study: NCT05436743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-Y Jelly, Topical Gel soaked packs
Description: Topical Gel used as lubricant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water soaked packs
Description: Water soaked packs for reduction of postoperative sore throat
Study: NCT05200234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nattokinase
Description: Nattokinase + standard treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo+ standard treatment
Study: NCT04781751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin injection
Description: Carpal tunnel syndrome sonagraphic injection
Study: NCT05863208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial intelligence
Description: ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial intelligence
Description: ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff vision
Description: Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition endoscope
Description: High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition endoscope
Description: High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-definition endoscope
Description: High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
Study: NCT05389904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Routine care
Description: Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Preemptive C. difficile infection prevention bundle
Description: Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
Study: NCT04276714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socket without Revofit system
Description: All the tests are evaluate during one week with the classical type of fittings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socket without Revofit system
Description: All the tests are evaluate during one week with the classical type of fittings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socket with Revofit system
Description: All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
Study: NCT06045260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
Study: NCT04276714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socket with Revofit system
Description: All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
Study: NCT06012370

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PRP injection
Description: Injection of PRP and hyaluronic acid
Study: NCT05812560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural changes
Description: application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
Study: NCT06333899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Continue maintenance monotherapy for total 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Continue maintenance monotherapy for total 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Continue maintenance monotherapy for total 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Continue maintenance monotherapy for total 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib with chemotherapy1
Description: Continue lorlatinib with BABY-POG chemotherapy backbone for 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib with chemotherapy 2
Description: Continue lorlatinib with HIT-SKK chemotherapy backbone for 42 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib post Radiation
Description: Continue lorlatinib monotherapy 28 days post completion of radiation therapy for 12 cycles
Study: NCT06195423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop OsteoARthritis (SOAR) program
Description: The SOAR program is a 6-month, online-delivered (videoconferencing), PT-guided knee health program which consists of;~1. Knee Camp: Includes interactive education, and 1:1 physiotherapy knee exam and counseling session to co-identify home-based exercise-therapy and physical activity goals to address participants' unique functional limitations. Participants are given a wrist-worn activity monitor to wear 24hours/day.~2. Individualized Weekly Home-based Exercise-Therapy and Physical Activity Program: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises and physical activity are tracked with an online form and the activity monitor. Participants can also attend an optional weekly group class.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counselling: Each week, participants attend a 1:1 physiotherapist counseling session to modify exercise-therapy and physical activity goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Well after ACLR program
Description: Participants in the minimal intervention CONTROL group will receive access to a 30-minute educational video (knee anatomy, ACLR information, general exercise, physical activity, and goal-setting principles), a best practice workbook, one video-recorded virtual session with a physiotherapist (naïve to SOAR) who will explain the booklet and answer questions but not volunteer information beyond the video or booklet and the same wrist-worn activity tracker as the experimental group.
Study: NCT04686331

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers for pneumonia
Description: Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~* Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis
Study: NCT05773378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary Intervention
Description: Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 10-week period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon Intervention
Description: Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 10-week period.
Study: NCT05517590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
Study: NCT06492915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-paclitaxel Injection
Description: Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Study: NCT03903224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Modified Pectoralis and Transversus Plane Blocks
Description: Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae block
Description: The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
Study: NCT06254729

Intervention type: OTHER
Intervention: Observational study
Description: Our study does not have any exposure factors.

Intervention type: OTHER
Intervention: Observational study
Description: Our study does not have any exposure factors.